Recent insights into the biology of Hodgkin lymphoma: Unraveling the mysteries of the Reed-Sternberg cell

Expert Review of Molecular Diagnostics

Volumn 7, Issue 6, 2007, Pages 805-820

  Roullet, Michele R ^a   Bagg, Adam ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

EBV; Hodgkin lymphoma; Immunoglobulin gene; NF B pathway; Reed Sternberg cell

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3,5 DI TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; AEG 35156; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BMS 345541; BORTEZOMIB; DENOSUMAB; GX 15070; IMATINIB; INTERLEUKIN 13 ANTIBODY; ISIS 345794; KM 2760; MONOCLONAL ANTIBODY; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NUTLIN 3; QLT 934; RITUXIMAB; SN 50; SRC 839; TEMSIROLIMUS; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UO 126; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL CYCLE ARREST; CELL PROLIFERATION; GENE AMPLIFICATION; GENE MUTATION; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE; METHYLATION; NEOPLASM; PHENOTYPE; REED STERNBERG CELL; REVIEW;

HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; NF-KAPPA B; PHENOTYPE; REED-STERNBERG CELLS; SIGNAL TRANSDUCTION;

EID: 36448994707     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.7.6.805     Document Type: Review

References (164)

1. Hodgkin T. On some morbid appearances of the assorbant glands and spleen. Med. Chir. Trans. 17, 69-97 (1832).
2. Reed D. On the pathological changes in Hodgkin's disease, with special reference to its relation to tuberculosis. Johns Hopkins Hosp. Rep. 10, 133-196 (1902).
3. Sternberg C. Uber eine eigenartige unter dem Bilde der Pseudoleukemic verlaufende Tuberculose des lymphatisshen Apparates. Z. Heilk. 19(21-90) (1898).
4. Weiss L, Chan JKC, MacLennan K. In: Hodgkin's Disease. Diehl V, Hoppe RT, Weiss LM (Eds). Lippincott Williams & Wilkins, PA, USA 101-102 (1999).
5. Pileri SA, Ascani S, Leoncini L et al. Hodgkin's lymphoma: the pathologist's viewpoint. J. Clin. Pathol. 55(3), 162-176 (2002).
6. Kuppers R. Molecular biology of Hodgkin's lymphoma. Adv. Cancer Res. 84, 277-312 (2002). •• Excellent comprehensive overview of the pioneering work with single neoplastic cells and dissection of transforming events.
7. Kuppers R, Hansmann ML. The Hodgkin and Reed/Sternberg cell. Int. J. Biochem. Cell Biol. 37(3), 511-517 (2005).
8. Kuppers R, Rajewsky K, Zhao M et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc. Natl Acad. Sci. USA 91(23), 10962-10966 (1994). •• Seminal discovery of immunoglobulin gene rearrangements in Hodgkin and Reed-Sternberg (HRS) cells.
9. Marafioti T, Hummel M, Foss HD et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 95(4), 1443-1450 (2000).
10. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J. Exp. Med. 184(4), 1495-1505 (1996).
11. Kuppers R, Schwering I, Brauninger A, Rajewsky K, Hansmann ML. Biology of Hodgkin's lymphoma. Ann. Oncol. 13(Suppl. 1), 11-18 (2002).
12. Muschen M, Rajewsky K, Brauninger A et al. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J. Exp. Med. 191(2), 387-394 (2000).
13. Seitz V, Hummel M, Marafioti T et al. Detection of clonal T-cell receptor γ-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease. Blood 95(10), 3020-3024 (2000).
14. Jaffe ES, Harris N, Stein H, Vardiman J. In: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues. World Health Organization, Lyon, France 239-253 (2001).
15. Greiner A, Tobollik S, Buettner M et al. Differential expression of activation-induced cytidine deaminase (AID) in nodular lymphocyte-predominant and classical Hodgkin lymphoma. J. Pathol. 205(5), 541-547 (2005).
16. Ohno T, Stribley JA, Wu G et al. Clonality in nodular lymphocyte-predominant Hodgkin's disease. N. Engl. J. Med. 337(7), 459-465 (1997).
17. Anagnostopoulos I, Hansmann ML, Franssila K et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 96(5), 1889-1899 (2000). •• Highly informative analysis of nodular lymphocyte predominant Hodgkin lymphoma (HL).
18. Carbone A, Gloghini A, Aldinucci D et al. Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. Br. J. Haematol. 117(2), 366-372 (2002).
19. Buettner M, Greiner A, Avramidou A, Jack HM, Niedobitek G. Evidence of abortive plasma cell differentiation in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. Hematol. Oncol. 23(3-4), 127-132 (2005).
20. Kuppers R, Schmitz R, Distler V et al. Pathogenesis of Hodgkin's lymphoma. Eur. J. Haematol. Suppl. (66), 26-33 (2005).
21. Theil J, Laumen H, Marafioti T et al. Defective octamer-dependent transcription is responsible for silenced immunoglobulin transcription in Reed-Sternberg cells. Blood 97(10), 3191-3196 (2001).
22. Laumen H, Nielsen PJ, Wirth T. The BOB.1 / OBF.1 co-activator is essential for octamer-dependent transcription in B cells. Eur. J. Immunol. 30(2), 458-469 (2000).
23. Yamamoto H, Kihara-Negishi F, Yamada T, Hashimoto Y, Oikawa T. Physical and functional interactions between the transcription factor PU.1 and the coactivator CBP. Oncogene 18(7), 1495-1501 (1999).
24. Torlakovic E, Tierens A, Dang HD, Delabie J. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease. Am. J. Pathol. 159(5), 1807-1814 (2001).
25. Jundt F, Kley K, Anagnostopoulos I et al. Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood 99(8), 3060-3062 (2002).
26. Re D, Muschen M, Ahmadi T et al. OCT-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res. 61(5), 2080-2084 (2001).
27. Stein H, Marafioti T, Foss HD et al. Down-regulation of BOB.1/OBF.1 and OCT2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 97(2), 496-501 (2001). • Key study showing impairment of immunoglobulin transcription and downregulation of B-cell transcription factors in classical HL (cHL).
28. Hertel CB, Zhou XG, Hamilton-Dutoit SJ, Junker S. Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma. Oncogene 21(32), 4908-4920 (2002).
29. Kee BL, Quong MW, Murre C. E2A proteins: essential regulators at multiple stages of B-cell development. Immunol. Rev. 175, 138-149 (2000).
30. Lin H, Grosschedl R. Failure of B-cell differentiation in mice lacking the transcription factor EBF. Nature 376(6537), 263-267 (1995).
31. Foss HD, Reusch R, Demel G et al. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 94(9), 3108-3113 (1999).
32. Medina KL, Pongubala JM, Reddy KL et al. Assembling a gene regulatory network for specification of the B cell fate. Dev. Cell 7(4), 607-617 (2004).
33. Schwering I, Brauninger A, Klein U et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 101(4), 1505-1512 (2003).
34. Mathas S, Janz M, Hummel F et al. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat. Immunol. 7(2), 207-215 (2006). • Important work providing further explanations for the aberrant phenotype of HRS cells.
35. Renne C, Martin-Subero JI, Eickernjager M et al. Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma. Am. J. Pathol. 169(2), 655-664 (2006).
36. Rivera R, Murre C. The regulation and function of the Id proteins in lymphocyte development. Oncogene 20(58), 8308-8316 (2001).
37. Roberts EC, Deed RW, Inoue T, Norton JD, Sharrocks AD. Id helix-loophelix proteins antagonize pax transcription factor activity by inhibiting DNA binding. Mol. Cell Biol. 21(2), 524-533 (2001).
38. Massari ME, Rivera RR, Voland JR et al. Characterization of ABF-1, a novel basic helix-loop-helix transcription factor expressed in activated B lymphocytes. Mol. Cell Biol. 18(6), 3130-3139 (1998).
39. Knight JC, Keating BJ, Kwiatkowski DP. Allele-specific repression of lymphotoxin-α by activated B cell factor-1. Nat. Genet. 36(4), 394-399 (2004).
40. Jundt F, Anagnostopoulos I, Forster R et al. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 99(9), 3398-3403 (2002).
41. Radtke F, Wilson A, Mancini SJ, MacDonald HR. Notch regulation of lymphocyte development and function. Nat. Immunol. 5(3), 247-253 (2004).
42. Schneider EM, Torlakovic E, Stuhler A et al. The early transcription factor GATA-2 is expressed in classical Hodgkin's lymphoma. J. Pathol. 204(5), 538-545 (2004).
43. Atayar C, Poppema S, Blokzijl T et al. Expression of the T-cell transcription factors, GATA-3 and T-BET, in the neoplastic cells of Hodgkin lymphomas. Am. J. Pathol. 166(1), 127-134 (2005).
44. Cossman J, Annunziata CM, Barash S et al. Reed-Sternberg cell genome expression supports a B-cell lineage. Blood 94(2), 411-416 (1999).
45. Kuppers R, Klein U, Schwering I et al. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J. Clin. Invest. 111(4), 529-537 (2003). •• Informative comparison of gene expression profiles of HRS cell lines with normal B cells and non-HLs.
46. Ushmorov A, Ritz O, Hummel M et al. Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression. Blood 104(10), 3326-3334 (2004).
47. Ushmorov A, Leithauser F, Sakk O et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 107(6), 2493-2500 (2006).
48. Natkunam Y, Hsi ED, Aoun P et al. Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival. Blood 109(1), 298-305 (2007).
49. Bargou RC, Leng C, Krappmann D et al. High-level nuclear NF-κB and OCT-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 87(10), 4340-4347 (1996).
50. Bargou RC, Emmerich F, Krappmann D et al. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J. Clin. Invest. 100(12), 2961-2969 (1997). •• One of the first studies demonstrating the activation of this central pathway in the pathogenesis of HL.
51. Jost PJ, Ruland J. Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 109(7), 2700-2707 (2007).
52. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IκBα gene in Hodgkin's disease suggest a tumour suppressor role for IκBα. Oncogene 18(20), 3063-3070 (1999).
53. Emmerich F, Theurich S, Hummel M et al. Inactivating IκBε mutations in Hodgkin/Reed-Sternberg cells. J. Pathol. 201(3), 413-420 (2003).
54. Annunziata CM, Safiran YJ, Irving SG, Kasid UN, Cossman J. Hodgkin disease: pharmacologic intervention of the CD40-NF κ B pathway by a protease inhibitor. Blood 96(8), 2841-2848 (2000).
55. Gires O, Zimber-Strobl U, Gonnella R et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. 16(20), 6131-6140 (1997).
56. Horie R, Watanabe T, Morishita Y et al. Ligand-independent signaling by overexpressed CD30 drives NF-κB activation in Hodgkin-Reed-Sternberg cells. Oncogene 21(16), 2493-2503 (2002).
57. Rodig SJ, Savage KJ, Nguyen V et al. TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin lymphoma from a subset of morphologically or immunophenotypically similar lymphomas. Am. J. Surg. Pathol. 29(2), 196-203 (2005).
58. Fiumara P, Snell V, Li Y et al. Functional expression of receptor activator of nuclear factor κB in Hodgkin disease cell lines. Blood 98(9), 2784-2790 (2001).
59. Zheng B, Fiumara P, Li YV et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 102(3), 1019-1027 (2003).
60. Dutton A, Reynolds GM, Dawson CW, Young LS, Murray PG. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J. Pathol. 205(4), 498-506 (2005).
61. Nagel S, Burek C, Venturini L et al. Comprehensive analysis of homeobox genes in Hodgkin lymphoma cell lines identifies dysregulated expression of HOXB9 mediated via ERK5 signaling and BMI1. Blood 109(7), 3015-3023 (2007).
62. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 21, 231-264 (2003).
63. Novak AJ, Darce JR, Arendt BK et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103(2), 689-694 (2004).
64. Hendriks J, Planelles L, de Jong-Odding J et al. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ. 12(6), 637-648 (2005).
65. Chiu A, Xu W, He B et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 109(2), 729-739 (2007).
66. Re D, Hofmann A, Wolf J, Diehl V, Staratschek-Jox A. Cultivated H-RS cells are resistant to CD95L-mediated apoptosis despite expression of wild-type CD95. Exp. Hematol. 28(3), 348 (2000).
67. Messineo C, Jamerson MH, Hunter E et al. Gene expression by single Reed-Sternberg cells: pathways of apoptosis and activation. Blood 91(7), 2443-2451 (1998).
68. Thomas RK, Kallenborn A, Wickenhauser C et al. Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. Am. J. Pathol. 160(4), 1521-1528 (2002).
69. Dutton A, O'Neil JD, Milner AE et al. Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. Proc. Natl Acad. Sci. USA 101(17), 6611-6616 (2004).
70. Kashkar H, Haefs C, Shin H et al. XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells. J. Exp. Med. 198(2), 341-347 (2003).
71. Kashkar H, Kronke M, Jurgensmeier JM. Defective Bax activation in Hodgkin B-cell lines confers resistance to staurosporine-induced apoptosis. Cell Death Differ. 9(7), 750-757 (2002).
72. Garcia JF, Camacho FI, Morente M et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 101(2), 681-689 (2003). •• Work revealing multiple biologic factors with a role in HRS cell survival in Epstein-Barr virus (EBV) and non-EBV-related cases.
73. Kube D, Holtick U, Vockerodt M et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood 98(3), 762-770 (2001).
74. Skinnider BF, Elia AJ, Gascoyne RD et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 99(2), 618-626 (2002).
75. Levy DE, Darnell JE Jr. STATs: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3(9), 651-662 (2002).
76. + Hodgkin cells. Cancer Res. 60(3), 549-552 (2000).
77. Kapp U, Yeh WC, Patterson B et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J. Exp. Med. 189(12), 1939-1946 (1999).
78. Alexander WS, Hilton DJ. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu. Rev. Immunol. 22, 503-529 (2004).
79. Weniger MA, Melzner I, Menz CK et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 25(18), 2679-2684 (2006).
80. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr. Opin. Cell Biol. 9(2), 240-246 (1997).
81. Mathas S, Hinz M, Anagnostopoulos I et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-κB. EMBO J. 21(15), 4104-4113 (2002).
82. + lymphomas and lymphomatoid papulosis. Mod. Pathol. 18(10), 1365-1370 (2005).
83. Janz M, Hummel M, Truss M et al. Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells. Blood 107(6), 2536-2539 (2006).
84. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 411(6835), 355-365 (2001).
85. Renne C, Willenbrock K, Kuppers R, Hansmann ML, Brauninger A. Autocrine-and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma. Blood 105(10), 4051-4059 (2005).
86. Renne C, Willenbrock K, Martin-Subero JI et al. High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. Leukemia 21(4), 780-787 (2007).
87. Teofili L, Di Febo AL, Pierconti F et al. Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood 97(4), 1063-1069 (2001).
88. Renne C, Hinsch N, Willenbrock K et al. The aberrant coexpression of several receptor tyrosine kinases is largely restricted to EBV-negative cases of classical Hodgkin's lymphoma. Int. J. Cancer 120(11), 2504-2509 (2007).
89. Trumper LH, Brady G, Bagg A et al. Single-cell analysis of Hodgkin and Reed-Sternberg cells: molecular heterogeneity of gene expression and p53 mutations. Blood 81(11), 3097-3115 (1993).
90. Kupper M, Joos S, von Bonin F et al. MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: results from single-cell polymerase chain reaction and molecular cytogenetic studies. Br. J. Haematol. 112(3), 768-775 (2001).
91. Falzetti D, Crescenzi B, Matteuci C et al. Genomic instability and recurrent breakpoints are main cytogenetic findings in Hodgkin's disease. Haematologica 84(4), 298-305 (1999).
92. + Hodgkin and Reed-Sternberg cells in 100% of analyzed cases of Hodgkin's disease. Blood 86(4), 1464-1468 (1995).
93. Martin-Subero JI, Klapper W, Sotnikova A et al. Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. Cancer Res. 66(21), 10332-10338 (2006). • Informative analysis of the genetics of HRS cells.
94. Joos S, Menz CK, Wrobel G et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood 99(4), 1381-1387 (2002).
95. Kluiver J, Kok K, Pfeil I et al. Global correlation of genome and transcriptome changes in classical Hodgkin lymphoma. Hematol. Oncol. 25(1), 21-29 (2007).
96. Garcia JF, Villuendas R, Algara P et al. Loss of p16 protein expression associated with methylation of the p16INK4A gene is a frequent finding in Hodgkin's disease. Lab. Invest. 79(12), 1453-1459 (1999).
97. Garcia MJ, Martinez-Delgado B, Cebrian A et al. Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's and CD30-positive non-Hodgkin's lymphomas. Am. J. Pathol. 161(3), 1007-1013 (2002).
98. Sanchez-Aguilera A, Delgado J, Camacho FI et al. Silencing of the p18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas. Blood 103(6), 2351-2357 (2004).
99. Murray PG, Qiu GH, Fu L et al. Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma. Oncogene 23(6), 1326-1331 (2004).
100. Ying J, Gao Z, Li H et al. Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies. Br. J. Haematol. 136(6), 829-832 (2007).
101. Staratschek-Jox A, Shugart YY, Strom SS, Nagler A, Taylor GM. Genetic susceptibility to Hodgkin's lymphoma and to secondary cancer: workshop report. Ann. Oncol. 13(Suppl. 1), 30-33 (2002).
102. Diepstra A, Niens M, te Meerman GJ, Poppema S, van den Berg A. Genetic susceptibility to Hodgkin's lymphoma associated with the human leukocyte antigen region. Eur. J. Haematol. Suppl. (66), 34-41 (2005).
103. Diepstra A, Niens M, Vellenga E et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus- negative Hodgkin's lymphoma. Lancet 365(9478), 2216-2224 (2005).
104. Niens M, Jarrett RF, Hepkema B et al. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV-positive Hodgkin lymphoma. Blood 110(9), 3310-3315 (2007).
105. Cordano P, Lake A, Shield L et al. Effect of IL-6 promoter polymorphism on incidence and outcome in Hodgkin's lymphoma. Br. J. Haematol. 128(4), 493-495 (2005).
106. Jundt F, Anagnostopoulos I, Bommert K et al. Hodgkin/Reed- Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 94(6), 2065-2071 (1999).
107. Foss HD, Herbst H, Gottstein S et al. Interleukin-8 in Hodgkin's disease. Preferential expression by reactive cells and association with neutrophil density. Am. J. Pathol. 148(4), 1229-1236 (1996).
108. van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltration Hodgkin's lymphoma. Am. J. Pathol. 154(6), 1685-1691 (1999).
109. Skinnider BF, Elia AJ, Gascoyne RD et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 97(1), 250-255 (2001).
110. Cossman J, Messineo C, Bagg A. Reed-Sternberg cell: survival in a hostile sea. Lab. Invest. 78(3), 229-235 (1998).
111. Marshall NA, Christie LE, Munro LR et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103(5), 1755-1762 (2004).
112. Wei WZ, Morris GP, Kong YC. Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol. Immunother. 53(2), 73-78 (2004).
113. Ishida T, Ishii T, Inagaki A et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res. 66(11), 5716-5722 (2006).
114. Atayar C, van den Berg A, Blokzijl T et al. Hodgkin lymphoma associated T-cells exhibit a transcription factor profile consistent with distinct lymphoid compartments. J. Clin. Pathol. 60(10), 1092-1097(2006).
115. Gandhi MK, Moll G, Smith C et al. Galectin-1 mediated suppression of EBV-specific T-cell immunity in classical Hodgkin's Lymphoma. Blood 110(4), 1326-1329 (2007).
116. Oudejans JJ, Jiwa NM, Kummer JA et al. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood 89(4), 1376-1382 (1997).
117. Alvaro T, Lejeune M, Salvado MT et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin. Cancer Res. 11(4), 1467-1473 (2005).
118. Doussis-Anagnostopoulou IA, Talks KL, Turley H et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed- Sternberg cells in Hodgkin's disease. J. Pathol. 197(5), 677-683 (2002).
119. Rickinson AB, Kieffe E. In: Epstein-Barr Virus in Fields Virology. Knipe DM, Howley PM (Eds). Lippincott-Raven, PA, USA (2001).
120. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N. Engl. J. Med. 320(8), 502-506 (1989).
121. Jarrett RF, MacKenzie J. Epstein-Barr virus and other candidate viruses in the pathogenesis of Hodgkin's disease. Semin. Hematol. 36(3), 260-269 (1999).
122. Glaser SL, Lin RJ, Stewart SL et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int. J. Cancer 70(4), 375-382 (1997).
123. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22(33), 5108-5121 (2003).
124. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 337(8737), 320-322 (1991).
125. Niedobitek G, Kremmer E, Herbst H et al. Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood 90(4), 1664-1672 (1997).
126. Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J. 17(6), 1700-1709 (1998).
127. Henderson S, Rowe M, Gregory C et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65(7), 1107-1115 (1991).
128. Eliopoulos AG, Stack M, Dawson CW et al. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors. Oncogene 14(24), 2899-2916 (1997).
129. Kim SH, Shin YK, Lee IS et al. Viral latent membrane protein 1 (LMP-1)-induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin's and Reed-Sternberg phenotype. Blood 95(1), 294-300 (2000).
130. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9(3), 405-411 (1998).
131. Brauninger A, Schmitz R, Bechtel D et al. Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. Int. J. Cancer 118(8), 1853-1861 (2006).
132. Kvale G, Hoiby EA, Pedersen E. Hodgkin's disease in patients with previous infectious mononucleosis. Int. J. Cancer 23(5), 593-597 (1979).
133. Gutensohn N, Cole P. Childhood social environment and Hodgkin's disease. N. Engl. J. Med. 304(3), 135-140 (1981).
134. Hjalgrim H, Smedby KE, Rostgaard K et al. Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res. 67(5), 2382-2388 (2007).
135. Chang ET, Zheng T, Weir EG et al. Childhood social environment and Hodgkin's lymphoma: new findings from a population-based case-control study. Cancer Epidemiol. Biomarkers Prev. 13(8), 1361-1370 (2004).
136. Glaser SL, Keegan TH, Clarke CA et al. Exposure to childhood infections and risk of Epstein-Barr virus - defined Hodgkin's lymphoma in women. Int. J. Cancer 115(4), 599-605 (2005).
137. Keegan TH, Glaser SL, Clarke CA et al. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. J. Clin. Oncol. 23(30), 7604-7613 (2005).
138. Benharroch D, Shemer-Avni Y, Myint YY et al. Measles virus: evidence of an association with Hodgkin's disease. Br. J. Cancer 91(3), 572-579 (2004).
139. Maggio E, Benharroch D, Gopas J et al. Absence of measles virus genome and transcripts in Hodgkin-Reed/Sternberg cells of a cohort of Hodgkin lymphoma patients. Int. J. Cancer 121(2), 448-453 (2007).
140. Rowlings PA, Curtis RE, Passweg JR et al. Increased incidence of Hodgkin's disease after allogeneic bone marrow transplantation. J. Clin. Oncol. 17(10), 3122-3127 (1999).
141. Kamel OW, van de Rijn M, Weiss LM et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N. Engl. J. Med. 328(18), 1317-1321 (1993).
142. Mariette X, Cazals-Hatem D, Warszawki J et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 99(11), 3909-3915 (2002).
143. Biggar RJ, Jaffe ES, Goedert JJ et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 108(12), 3786-3791 (2006).
144. Herida M, Mary-Krause M, Kaphan R et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J. Clin. Oncol. 21(18), 3447-3453 (2003).
145. Engels EA, Pfeiffer RM, Goedert JJ et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 20(12), 1645-1654 (2006).
146. Gloghini A, Carbone A. Why would the incidence of HIV-associated Hodgkin lymphoma increase in the setting of improved immunity? Int. J. Cancer 120(12), 2753-2754 (2007).
147. Savage KJ, Monti S, Kutok JL et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102(12), 3871-3879 (2003).
148. Rosenwald A, Wright G, Leroy K et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 198(6), 851-862 (2003).
149. Joos S, Granzow M, Holtgreve-Grez H et al. Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int. J. Cancer 103(4), 489-495 (2003).
150. Traverse-Glehen A, Pittaluga S, Gaulard P et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am. J. Surg. Pathol. 29(11), 1411-1421 (2005). • Excellent paper highlighting cases with overlapping features of both cHL and primary mediastinal B-cell lymphoma.
151. Hsi ED, Sup SJ, Alemany C et al. MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis. Am. J. Clin. Pathol. 125(5), 776-782 (2006).
152. Copie-Bergman C, Plonquet A, Alonso MA et al. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod. Pathol. 15(11), 1172-1180 (2002).
153. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84(5), 1361-1392 (1994).
154. Willenbrock K, Kuppers R, Renne C et al. Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma. Haematologica 91(5), 596-604 (2006). • Comparison of transcriptional profiles of cHL with anaplastic large-cell lymphoma.
155. Vanhentenrijk V, Van den Bempt I, Dierickx D et al. Relationship between classic Hodgkin lymphoma and overlapping large cell lymphoma investigated by comparative expressed sequence hybridization expression profiling. J. Pathol. 210(2), 155-162 (2006).
156. DeVita VT Jr, Simon RM, Hubbard SM et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann. Intern. Med. 92(5), 587-595 (1980).
157. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N. Engl. J. Med. 327(21), 1478-1484 (1992).
158. Franklin J, Pluetschow A, Paus M et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann. Oncol. 17(12), 1749-1760 (2006).
159. Sup SJ, Alemany CA, Pohlman B et al. Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. J. Clin. Oncol. 23(16), 3773-3779 (2005).
160. Diepstra A, van Imhoff GW, Karim-Kos HE et al. HLA Class II expression by Hodgkin's Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J. Clin. Oncol. 25(21), 3101-3108 (2007).
161. Casasnovas RO, Mounier N, Brice P et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. 25(13), 1732-1740 (2007).
162. Tecchio C, Nadali G, Scapini P et al. High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma. Br. J. Haematol. 137(6), 553-559 (2007).
163. Fuchs M, Diehl V, Re D. Current strategies and new approaches in the treatment of Hodgkin's lymphoma. Pathobiology 73(3), 126-140 (2006).
164. Buglio D, Georgakis G, Younes A. Novel small-molecule therapy of Hodgkin lymphoma. Expert Rev. Anticancer Ther. 7(5), 735-740 (2007).